BioNTech (BNTX) stock is down nearly 20% at the time of writing after the German company posted a Q4 loss, issued muted guidance, and said its cofounders will depart by the end of this year CEO Uğur ...
Hosted on MSN
Is BioNTech SE (BNTX) a good stock to buy now?
We came across a bullish thesis on BioNTech SE on Memyselfandi007’s Substack. In this article, we will summarize the bulls’ thesis on BNTX. BioNTech SE's share was trading at $103.80 as of March 4th.
BioNTech SE Sponsored ADR (BNTX) shares rallied 11.8% in the last trading session to close at $118. This move can be attributable to notable volume with a higher number of shares being traded than in ...
BioNTech (BNTX), the partner of Pfizer (PFE) for the Comirnaty COVID-19 vaccine, fell 18% in the premarket on Tuesday after its Q4 2025 financials, as its full-year outlook fell short of Street ...
BioNTech SE is transitioning from a COVID-19 vaccine story to a late-stage oncology platform with a robust $17B cash position. At a $27.6B market cap and ~$11B enterprise value, BNTX's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results